Tirzepatide is a new injectable medication that results in substantial weight loss over 72 weeks of the trial. What is the risk of rebound weight gain if medication is stopped? I review the SURMOUNT1 trial published in the NEJM. New telemedicine site for weight loss treatment by physicians and APP providers may help patients having a hard time finding local providers to prescribe weight loss medications. www.joinmochi.com